Diana Viray, Edwin ten Winkel
BBP492 is a tetrodotoxin like compound that is not identical to any known natural occuring tetrodotoxin compound. In a phase II trial effects of Durogesic® patches on pain in cancerpatients were compared to BBP 492.
Both groups could use oxycodon against 'breakthrough' pain.
On a VAS, patients on BBP492 scored significantly better on pain control than patients on Durogesic® when compared to baseline. Also, patients on BBP 492 had significantly lower need for use of oxycodon during the trial.
Durogesic® is a brand name of Janssen-Cilag
